Due to more powerful drugs [23] and the introduction of a targeted therapy for molecularly selected patient subgroups like patients with an EGFR activation mutation, impressive improvements in the treatment of lung cancer patients were achieved [24]. The gene discussed is EGFR; the disease is lung carcinoma.